Role of Cord Blood Cytokines and Perinatal Factors in Prediction of Retinopathy of Prematurity
NCT ID: NCT04769661
Last Updated: 2021-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-05-01
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Mydriatic Eye Drops on Cerebral and Mesenteric Oxygenation in Preterm Infants
NCT01305720
Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants
NCT00799721
Vitamin A in Cord Blood and Preterm Outcomes
NCT07296393
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study
NCT05782101
Preterm Infants REtinalMicrovascular Alterations by Means of OCT Angiography
NCT05699668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Clinical evaluation:
* History taking including name, sex and age at diagnosis of ROP.
* Detailed obstetric history \[maternal age, type of conception (natural, hormonal or in vitro fertilization), type of delivery (vaginal or cesarean section), single or multiple gestation, pregnancy complications (hypertension, diabetes mellitus, placental abruption, premature rupture of membranes, chorioamnionitis), drug history including steroid treatment received prior to delivery\].
* Neonatal data \[Gestational age by weeks calculated from the last menstrual period and confirmed by physical examination, birth weight in grams, Apgar scores at 1 and 5 minutes, weight appropriate or small for gestational age, presence of hypoxia during or after delivery, need for oxygen therapy (mode of delivery, duration, oxygen saturation), presence of clinical sepsis, Respiratory distress syndrome, anemia or the need of blood transfusion\].
* Complete physical examination will be done to all babies including cardiac, chest, abdominal and neurological examination.
2. Laboratory assessment:
A- Routine assessment:
1. Complete blood count (CBC) for the mother.
2. CBC for all infants.
B- Immunological assessment: level of Interleukin-6 and 8, and Tumor necrosis factor-α will be assessed:
Umbilical cord blood will be sampled by venipuncture of umbilical vein at birth under complete aseptic conditions for determination of cytokine level. Cord blood samples will be collected on serum separator tube with gel and then are allowed to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000xg. Serum will be removed and stored at ≤ -20 ˚c.till assessment by Lab-scan 3D using Luminex assay multiplex kits
3- Fundus examination After training on fundus examination at ophthalmology department, I will do it for babies. Current guidelines by the American Academy of Ophthalmology and Pediatrics, and American Association for Pediatric Ophthalmology and Strabismus recommend that all infants with gestational age ≤32 weeks or birth weight ≤1500g should be screened for retinopathy of prematurity (ROP). Unnecessary examinations may increase the medical costs for ROP screening. First examination will be done at age of 4 to 6 weeks of age, then every 2-3 weeks until their vessels have grown out to the ora serrate and the retina is considered mature. If ROP is diagnosed, examination will be done every 1-2 weeks according to the severity of the disease. The stage of ROP is the highest stage during all fundus examinations done.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cytokines
Doing cord blood cytokines level in preterm infants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Hour
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rewaa Mohammed
Role of cord blood cytokines and perinatal factors in prediction of retinopathy of prematurity
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
yasser farouk, lecturer
Role: STUDY_DIRECTOR
assiut university children hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
1. Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol. 2013;40:185-200. PMID: 23719304 DOI: 10.1016/j.clp.2013.02.001 2. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35-49. Pediatr Res. 2013 Dec;74 Suppl 1(Suppl 1):17-34. doi: 10.1038/pr.2013.204.PMID: 24366461 3. Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmstrom GE. Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol. 2009;127:1315-9. PMID: 19822848 DOI: 10.1001/archophthalmol.2009.244 4. Lynch AM, Wagner BD, Hodges JK, et al. The relationship of the subtypes of preterm birth with retinopathy of prematurity. Am J Obstet Gynecol. 2017;217:354. 9. PMID: 28545834 DOI: 10.1016/j.ajog.2017.05.029
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCPR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.